FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166429211> ?p ?o ?g. }

• W2166429211 abstract "The human EGF receptor family (HER9s) consists of two clinically validated drug targets (EGFR and Her2), and two receptors (Her3 and Her4) which are the subject of intensive preclinical and early clinical investigation. Although drugs inhibiting both EGFR and Her2 show significant antitumor activity in the clinic, the acquisition of resistance is a hallmark of these and other targeted therapies. In the case of both targets, one of the emerging resistance mechanisms is the co-expression of other members of the EGFR superfamily. It was recently shown that Her2 co-expression mediates resistance in cetuximab treated head and neck cancer (Sci Transl Med 7(3)99). Similarly, much attention has been paid to Her3 both as a bona fide drug target as well as a resistance mechanism. Finally, Her4, though less well studied appears to be another resistance mechanism. Her3 is usually expressed at much lower levels than EGFR and Her2 (often By using trypsin digestion mapping, we identified multiple unique peptide sequences from Her3 which were quantitated by SRM Mass spectrometry. Our assay was preclinically validated using the single most sensitive peptide, quantitating Her3 expression in multiple different cell lines, and human NSCLC primary tumor xenografts. These preclinical studies were then extended by assessing the expression levels of Her3 in two cohorts of clinical tumor tissue which had been treated with Her family antagonists. First, we measured Her3 expression in a set of neoadjuvant gefitinib treated NSCLC tumors. In this cohort, 12/15 tumor showed low but measurable levels of Her3 expression, ranging from 50–100 amol/ug tumor tissue. In a second tissue set, we measured Her3 expression in a cohort of advanced (Stage III-IV) breast cancer tissues which had undergone post resection adjuvant treatment with trastuzumab. These breast cancer samples demonstrated a higher level of expression of Her3, ranging from 50 − 250amol/ug tumor tissue, and 15/18 tumors were Her3 positive. In both studies, the relationship between Her family expression and response to either gefitinib or trastuzumab is currently under study. It is critically important to understand mechanisms of resistance in patients undergoing targeted therapies, and Liquid Tissue-SRM promises to be a platform which can deliver extremely high sensitivity, absolute specificity as well as multiplexing capabilities to assess the four HER family targets in unison. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A152." @default.
• W2166429211 created "2016-06-24" @default.
• W2166429211 creator A5015037150 @default.
• W2166429211 creator A5025548835 @default.
• W2166429211 creator A5038897416 @default.
• W2166429211 creator A5044900701 @default.
• W2166429211 creator A5045522995 @default.
• W2166429211 creator A5053349466 @default.
• W2166429211 creator A5055278295 @default.
• W2166429211 creator A5070673981 @default.
• W2166429211 date "2011-11-12" @default.
• W2166429211 modified "2023-09-28" @default.
• W2166429211 title "Abstract A152: Multiplex assay in FFPE tissues to simulateously quantify the human EGF receptor (HER1–4) family proteins: Implications for targeted therapy and resistance to therapy." @default.
• W2166429211 doi "https://doi.org/10.1158/1535-7163.targ-11-a152" @default.
• W2166429211 hasPublicationYear "2011" @default.
• W2166429211 type Work @default.
• W2166429211 sameAs 2166429211 @default.
• W2166429211 citedByCount "0" @default.
• W2166429211 crossrefType "proceedings-article" @default.
• W2166429211 hasAuthorship W2166429211A5015037150 @default.
• W2166429211 hasAuthorship W2166429211A5025548835 @default.
• W2166429211 hasAuthorship W2166429211A5038897416 @default.
• W2166429211 hasAuthorship W2166429211A5044900701 @default.
• W2166429211 hasAuthorship W2166429211A5045522995 @default.
• W2166429211 hasAuthorship W2166429211A5053349466 @default.
• W2166429211 hasAuthorship W2166429211A5055278295 @default.
• W2166429211 hasAuthorship W2166429211A5070673981 @default.
• W2166429211 hasConcept C114851261 @default.
• W2166429211 hasConcept C121608353 @default.
• W2166429211 hasConcept C126322002 @default.
• W2166429211 hasConcept C170493617 @default.
• W2166429211 hasConcept C2777506169 @default.
• W2166429211 hasConcept C2779438470 @default.
• W2166429211 hasConcept C2779998722 @default.
• W2166429211 hasConcept C2780580887 @default.
• W2166429211 hasConcept C2781188995 @default.
• W2166429211 hasConcept C2781230642 @default.
• W2166429211 hasConcept C502942594 @default.
• W2166429211 hasConcept C526805850 @default.
• W2166429211 hasConcept C54355233 @default.
• W2166429211 hasConcept C60644358 @default.
• W2166429211 hasConcept C71924100 @default.
• W2166429211 hasConcept C86803240 @default.
• W2166429211 hasConceptScore W2166429211C114851261 @default.
• W2166429211 hasConceptScore W2166429211C121608353 @default.
• W2166429211 hasConceptScore W2166429211C126322002 @default.
• W2166429211 hasConceptScore W2166429211C170493617 @default.
• W2166429211 hasConceptScore W2166429211C2777506169 @default.
• W2166429211 hasConceptScore W2166429211C2779438470 @default.
• W2166429211 hasConceptScore W2166429211C2779998722 @default.
• W2166429211 hasConceptScore W2166429211C2780580887 @default.
• W2166429211 hasConceptScore W2166429211C2781188995 @default.
• W2166429211 hasConceptScore W2166429211C2781230642 @default.
• W2166429211 hasConceptScore W2166429211C502942594 @default.
• W2166429211 hasConceptScore W2166429211C526805850 @default.
• W2166429211 hasConceptScore W2166429211C54355233 @default.
• W2166429211 hasConceptScore W2166429211C60644358 @default.
• W2166429211 hasConceptScore W2166429211C71924100 @default.
• W2166429211 hasConceptScore W2166429211C86803240 @default.
• W2166429211 hasLocation W21664292111 @default.
• W2166429211 hasOpenAccess W2166429211 @default.
• W2166429211 hasPrimaryLocation W21664292111 @default.
• W2166429211 hasRelatedWork W1566993644 @default.
• W2166429211 hasRelatedWork W1593280117 @default.
• W2166429211 hasRelatedWork W1754797577 @default.
• W2166429211 hasRelatedWork W1997285329 @default.
• W2166429211 hasRelatedWork W2008914408 @default.
• W2166429211 hasRelatedWork W2028061086 @default.
• W2166429211 hasRelatedWork W2031018710 @default.
• W2166429211 hasRelatedWork W2049457767 @default.
• W2166429211 hasRelatedWork W2119672124 @default.
• W2166429211 hasRelatedWork W2288796833 @default.
• W2166429211 hasRelatedWork W2322129576 @default.
• W2166429211 hasRelatedWork W2403079980 @default.
• W2166429211 hasRelatedWork W2522589922 @default.
• W2166429211 hasRelatedWork W2783280691 @default.
• W2166429211 hasRelatedWork W2888198746 @default.
• W2166429211 hasRelatedWork W2895955393 @default.
• W2166429211 hasRelatedWork W2930274452 @default.
• W2166429211 hasRelatedWork W2955270445 @default.
• W2166429211 hasRelatedWork W3127763729 @default.
• W2166429211 hasRelatedWork W894871824 @default.
• W2166429211 isParatext "false" @default.
• W2166429211 isRetracted "false" @default.
• W2166429211 magId "2166429211" @default.
• W2166429211 workType "article" @default.